VOLTAREN OPH SOLN Rx
Generic Name and Formulations:
Diclofenac sodium 0.1%.
Indications for VOLTAREN OPH SOLN:
Post-op inflammation after cataract extraction. Photophobia and pain in corneal refractive surgery.
Cataract surgery: 1 drop 4 times daily beginning 24 hrs post-op for 2 weeks. Corneal refractive surgery: 1–2 drops within the hour prior to surgery, then within 15 minutes post-op, then 4 times daily for up to 3 days.
Bleeding tendencies. Complicated or repeat ocular surguries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. May delay wound healing. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Should not be used by patients currently wearing soft contact lenses. Monitor refractive stability for 1 year. Pregnancy (Cat.C); avoid during late pregnancy. Nursing mothers: not recommended.
Caution with medications that prolong bleeding time. Concomitant use of topical steroids may increase potential for healing problems.
Burning, stinging, dry eye, other ocular effects, increased bleeding (including hyphemas).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma